Bvf Inc Centessa Pharmaceuticals PLC Transaction History

Bvf Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$5.52 - $8.03 $1.81 Million - $2.64 Million	-328,484 Reduced 3.61%	8,774,570 $69.8 Million
Q3 2023 Nov 14, 2023	SELL	$6.01 - $8.24 $1.92 Million - $2.64 Million	-320,161 Reduced 3.4%	9,103,054 $58.9 Million
Q1 2023 May 15, 2023	BUY	$3.03 - $4.0 $7.66 Million - $10.1 Million	2,528,870 Added 36.68%	9,423,215 $36.3 Million
Q2 2022 Aug 15, 2022	BUY	$3.18 - $9.85 $16.3 Million - $50.6 Million	5,138,800 Added 292.72%	6,894,345 $33.6 Million
Q1 2022 May 16, 2022	BUY	$7.45 - $11.59 $9.69 Million - $15.1 Million	1,301,000 Added 286.22%	1,755,545 $15.7 Million
Q4 2021 Feb 14, 2022	BUY	$10.99 - $17.54 $5 Million - $7.97 Million	454,545 New	454,545 $5.12 Million
Q3 2021 Nov 15, 2021	SELL	$16.7 - $23.11 $983,630 - $1.36 Million	-58,900 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$21.71 - $25.66 $1.28 Million - $1.51 Million	58,900 New	58,900 $1.31 Million

108

118M

5.9K

53K

Ticker CNTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,339,296
Market Cap $1.61B
Description
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; an...

Get notified when there are updates to the investment portfolio of Bvf Inc, based on Form 13F filings with the SEC.

Stay updated on Bvf Inc with notifications on news.